“Disappointed but not surprised” by the FDA’s refusal to go back on its surprise withdrawal of the special protocol assessment (SPA) deal for the trial known as ANCHOR, Amarin Corp. plc is moving to the next step in seeking a broader label on the triglyceride-lowering therapy Vascepa (icosapent ethyl), said CEO John Thero.